No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.

No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.

<h4>Background</h4>The objective of this study was to assess the benefit of temporary combination antiretroviral therapy (cART) during primary HIV infection (PHI).<h4>Methods and findings</h4>Adult patients with laboratory evidence of PHI were recruited in 13 HIV treatment ce...

Full description

Bibliographic Details
Main Authors: Marlous L Grijsen, Radjin Steingrover, Ferdinand W N M Wit, Suzanne Jurriaans, Annelies Verbon, Kees Brinkman, Marchina E van der Ende, Robin Soetekouw, Frank de Wolf, Joep M A Lange, Hanneke Schuitemaker, Jan M Prins, Primo-SHM Study Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS Medicine
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22479156/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22479156/?tool=EBI

Similar Items